The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Regeneron's Japan sales performance.
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission as the first and only targeted medicine for eosinophilic oesophagitis (EoE), the companies announced.
Sanofi and Regeneron’s Dupixent (dupilumab) has been recommended for use in the EU to treat severe atopic dermatitis in children aged six months to five years who are candidates for ... this chronic disease," George Yancopoulos, Regeneron’s president
In November 2022, the company announced a collaboration and licensing agreement with Regeneron to create conditionally-activated investigational bispecific cancer therapies. ... The partnership will also utilise the company’s Probody platform, along
Sanofi and Regeneron’s Dupixent (dupilumab) has been recommended by the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) to treat adults and adolescent patients
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) for the treatment of adult patients with moderate-to-severe prurigo nodularis who are candidates for systemic ... devastating impact on their day-to-day lives,
Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...